Therapy Areas: Respiratory
Evogene completes Phase 1 study of BMC128 in combination with Nivolumab
3 June 2026 - Computational chemistry company Evogene Ltd (Nasdaq:EVGN) (TASE:EVGN) announced on Tuesday the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a ratio...
Cumberland Pharmaceuticals and Vanderbilt Health report data from Phase 2a trial of ifetroban to prevent cancer metastasis
3 June 2026 - Specialty pharmaceutical company Cumberland Pharmaceuticals Inc (Nasdaq:CPIX) and healthcare provider Vanderbilt Health on Tuesday announced data from a Phase 2a clinical trial of ifetro...
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
2 June 2026 - US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Monday that it has received marketing authorisation from the European Commission for IMDYLLTRA (tarlatamab) as a monotherapy...
Haisco receives US FDA approval for anaesthetic Cipepofol
...
hVIVO secures Decoy Therapeutics consultancy contract for antiviral development
1 June 2026 - Clinical development partner hVIVO plc (AIM: HVO) announced on Monday that it has signed a consultancy agreement with Decoy Therapeutics to support the development of its respiratory ant...
Dizal presents positive NSCLC data for DZD6008 and golidocitinib at ASCO 2026
1 June 2026 - Chinese biopharmaceutical company Dizal (SSE:688192) announced on Saturday the presentation of two studies in non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical ...